Actively Recruiting
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Led by EtiraRx Australia Pty Ltd · Updated on 2025-09-18
15
Participants Needed
4
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
CONDITIONS
Official Title
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be at least 18 years of age at the time of signing the informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
- Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Adequate baseline organ function and hematologic function
- Life expectancy >3 months
You will not qualify if you...
- Systemic anti cancer therapy within 4 weeks of first dose of study drug
- Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
- Uncontrolled intercurrent illnesses
- Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Macquarie University Health
Ryde, New South Wales, Australia, 2109
Actively Recruiting
2
The Kinghorn Cancer Center
Sydney, New South Wales, Australia, 2010
Actively Recruiting
3
Cancer Research SA
Adelaide, South Australia, Australia, 5000
Actively Recruiting
4
Icon Cancer Centre Adelaide
Adelaide, South Australia, Australia, 5037
Actively Recruiting
Research Team
R
Research Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here